Hikma Pharmaceuticals Plc’s (LON:HIK) Add Rating Reaffirmed at Numis Securities Ltd
Hikma Pharmaceuticals Plc (LON:HIK)‘s stock had its “add” rating reaffirmed by analysts at Numis Securities Ltd in a note issued to investors on Friday, Marketbeat Ratings reports. They presently have a GBX 1,560 ($20.32) target price on the stock. Numis Securities Ltd’s target price would indicate a potential upside of 21.31% from the company’s previous close.
Several other research firms have also issued reports on HIK. HSBC Holdings plc reaffirmed a “reduce” rating and issued a GBX 1,800 ($23.44) price objective on shares of Hikma Pharmaceuticals Plc in a research note on Friday, May 5th. J P Morgan Chase & Co reduced their price objective on shares of Hikma Pharmaceuticals Plc from GBX 2,400 ($31.25) to GBX 1,800 ($23.44) and set a “neutral” rating for the company in a research note on Friday, May 12th. Jefferies Group LLC lowered shares of Hikma Pharmaceuticals Plc to an “underperform” rating and reduced their price objective for the company from GBX 2,162 ($28.15) to GBX 1,450 ($18.88) in a research note on Wednesday, May 17th. Citigroup Inc. reaffirmed a “neutral” rating and issued a GBX 1,550 ($20.18) price objective on shares of Hikma Pharmaceuticals Plc in a research note on Wednesday, June 28th. Finally, Barclays PLC reaffirmed an “overweight” rating and issued a GBX 2,200 ($28.65) price objective on shares of Hikma Pharmaceuticals Plc in a research note on Monday, July 3rd. Two analysts have rated the stock with a sell rating, four have assigned a hold rating and four have issued a buy rating to the company’s stock. Hikma Pharmaceuticals Plc has a consensus rating of “Hold” and an average target price of GBX 1,892.10 ($24.64).
Hikma Pharmaceuticals Plc (HIK) traded down 1.15% during mid-day trading on Friday, hitting GBX 1286.00. The stock had a trading volume of 514,609 shares. The firm’s market cap is GBX 3.10 billion. The company has a 50-day moving average of GBX 1,412.94 and a 200-day moving average of GBX 1,776.73. Hikma Pharmaceuticals Plc has a 12-month low of GBX 1,277.00 and a 12-month high of GBX 2,354.00.
Hikma Pharmaceuticals Plc Company Profile
Hikma Pharmaceuticals Plc is a pharmaceutical company. The Company is focused on developing, manufacturing and marketing a range of both branded and non-branded generic and in-licensed products. The Company’s segments include Branded, Injectables, Generics and Others. It sells branded generics and in-licensed patented products across the Middle East and North Africa (MENA) region and other markets.
Receive News & Ratings for Hikma Pharmaceuticals Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals Plc and related companies with MarketBeat.com's FREE daily email newsletter.